Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 30;15(19):4810.
doi: 10.3390/cancers15194810.

The Role of Non-Coding RNAs in Myelodysplastic Neoplasms

Vasileios Georgoulis  1 , Epameinondas Koumpis  1 , Eleftheria Hatzimichael  1   2
Affiliations
Review

The Role of Non-Coding RNAs in Myelodysplastic Neoplasms

Vasileios Georgoulis et al. Cancers (Basel). .

Abstract

Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs, including the less studied circRNA, siRNA, piRNA, and snoRNA as potential prognostic and/or predictive biomarkers or therapeutic targets in MDS.

Keywords: circRNA; lncRNA; microRNA; myelodysplastic syndromes; non-coding RNA; piRNA; snoRNA; tRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Non-coding RNAs, such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) can be extracted directly from plasma or serum or from mononuclear cells derived from either the peripheral blood or the bone marrow and can serve as prognostic or predictive biomarkers.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Shastri A., Will B., Steidl U., Verma A. Stem and progenitor cell alterations in myelodysplastic syndromes. Blood. 2017;129:1586–1594. doi: 10.1182/blood-2016-10-696062. - DOI - PMC - PubMed
    1. Cazzola M. Myelodysplastic Syndromes. N. Engl. J. Med. 2020;383:1358–1374. doi: 10.1056/NEJMra1904794. - DOI - PubMed
    1. Khoury J.D., Solary E., Abla O., Akkari Y., Alaggio R., Apperley J.F., Bejar R., Berti E., Busque L., Chan J.K.C., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–1719. doi: 10.1038/s41375-022-01613-1. - DOI - PMC - PubMed
    1. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088. doi: 10.1182/blood.V89.6.2079. - DOI - PubMed
    1. Bernard E., Tuechler H., Greenberg P.L., Hasserjian R.P., Ossa J.E.A., Nannya Y., Devlin S.M., Creignou M., Pinel P., Monnier L., et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evidence. 2022;1:EVIDoa2200008. doi: 10.1056/EVIDoa2200008. - DOI - PubMed